Ocumension Therapeutics (HKG:1477)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
7.50
+0.05 (0.67%)
Apr 29, 2026, 4:08 PM HKT
38.38%
Market Cap 6.12B
Revenue (ttm) 895.09M
Net Income (ttm) -176.74M
Shares Out 815.38M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE 163.62
Dividend n/a
Ex-Dividend Date n/a
Volume 301,000
Average Volume 884,211
Open 7.45
Previous Close 7.45
Day's Range 7.40 - 7.55
52-Week Range 5.01 - 12.23
Beta 0.48
RSI 46.43
Earnings Date Mar 26, 2026

About Ocumension Therapeutics

Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, age-related mac... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 552
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1477
Full Company Profile

Financial Performance

In 2025, Ocumension Therapeutics's revenue was 804.35 million, an increase of 92.75% compared to the previous year's 417.31 million. Losses were -158.82 million, -40.80% less than in 2024.

Financial numbers in CNY Financial Statements

News

There is no news available yet.